Center talks with Pfizer on Covid-19 vaccine’s for children

Must read

Pfizer, the world’s largest pharmaceutical company, told the Indian government on Wednesday that its Covid-19 vaccine can be given to anyone aged 12 and up and stored for a month at 2-8 degrees Celsius.

In some places, the Pfizer vaccine, which was developed in partnership with the German biotechnology firm BioNTech, is the only vaccine now being given to children. On May 14, the US Food and Drug Administration approved the Pfizer-BioNTech vaccine for children aged 12 to 15. On May 5, Canada approved its vaccine for children. The European Medicines Agency is also looking into its application in chinese medicine.

The initial caution recommended that Pfizer vaccinations be maintained at a temperature of minus 70 degrees Celsius, which was thought to be nearly difficult for tropical nations with limited cold storage infrastructure. However, the company has subsequently changed the recommendation, stating that the vaccines may now be stored at minus 25 degrees and even 2-8 degrees for up to a month.

Pfizer announced on May 26 that it is willing to export five crore vaccine doses over four months, beginning with one crore in July, one in August, two crore in September, and one crore in October. The manufacturer, on the other hand, has agreed to hold talks with the Indian government and accept payments straight from them. Pfizer and Moderna had previously refused to sell vaccines directly to state.

Pfizer also discussed indemnity and liability protection in the event of any lawsuits arising from the use of their vaccine. Pfizer pursues indemnity and liability safeguards in all of its agreements, which are in compliance with local laws in 116 countries across the world. Contracts with governments for the supply of required vaccines during public health emergencies sometimes include indemnification clauses.

- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article